Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05045638 · ClinicalTrials.gov registry record · Phase 1
Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants
A Phase 1 study of Healthy Participants, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT05045638: Completed Phase 1 study of Healthy Participants, sponsored by Amgen.
NCT05045638 is a Phase 1 study of Healthy Participants that has completed, run by Amgen. The registered enrollment target is 13 participants, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05045638, a Phase 1 study of Healthy Participants, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to determine the effect of sotorasib on the pharmacokinetics (PK) of rosuvastatin, and to assess the PK of rosuvastatin when administered alone, in healthy participants.
Primary Outcome
The pharmacokinetic (PK) parameters were determined using standard non-compartmental methods.
Conditions Studied
Interventions
- DRUG Sotorasib
- DRUG Rosuvastatin
Study Locations (1)
Florida
- Covance Clinical Research Unit - Daytona Beach - Daytona Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-08-20 |
| Est. Completion | 2021-10-10 |
| Phase | Phase 1 |
What the finished NCT05045638 record still lists
NCT05045638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Sotorasib is the first listed.
NCT05045638 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05045638 about?
NCT05045638 is a clinical study titled "Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants". A study to determine the effect of sotorasib on the pharmacokinetics (PK) of rosuvastatin, and to assess the PK of rosuvastatin when administered alone, in healthy participants.
What is the current status of trial NCT05045638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-08-20. Estimated completion is 2021-10-10.
What conditions does trial NCT05045638 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT05045638?
The interventions under investigation include: Sotorasib (DRUG), Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT05045638?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05045638 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05045638's enrollment target sits among peer trials
13 110th of 119 higher than 9 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI